Biophytis (BPTSY) plans first Phase-3 sarcopenia trial with consortium

Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia.

Rhea-AI Filing Summary

Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia. The announcement was furnished on a Form 6-K and the press release is provided as Exhibit 99.1.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biophytis (BPTSY) announce in its Form 6-K?

Biophytis announced partnering with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first Phase-3 trial in sarcopenia.

Which investors are involved with Biophytis (BPTSY)?

The consortium includes RONGHUI RENHE Life Technology as named in the announcement.

What stage is Biophytis’ sarcopenia program?

The company announced plans to launch the first Phase-3 trial in sarcopenia.

Where can I find the detailed announcement for Biophytis (BPTSY)?

The full press release is attached as Exhibit 99.1 to the Form 6-K.

When was the Biophytis (BPTSY) announcement made?

The announcement is dated October 13, 2025.

What filing type did Biophytis (BPTSY) use for this update?

Biophytis furnished a Form 6-K as a report of a foreign private issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 06:08 AM EDT Learn about SEC filing dates

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: October 13, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On October 13, 2025, Biophytis S.A. issued a press release announcing that Biophytis and a consortium of investors including RONGHUI RENHE Life Technology join forces to finance and launch first ever Phase-3 trial in sarcopenia. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated October 13, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: October 13, 2025	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer